6-Deoxy-6-methyl-hexose

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-Deoxy-6-methyl-hexose
• 英文别名: 6-ethyloxane-2,3,4,5-tetrol
• 化学式: C₇H₁₄O₅
• 分子量: 178.18
• InChiKey: HIPAIKSXHJHWJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  90.2
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• AMINOACID DERIVATIVES CONTAINING A DISULFANYL GROUP IN THE FORM OF MIXED DISULFANYL AND AMINOPEPTIDASE N INHIBITORS
  申请人：Roques Bernard

  公开号：US20090012153A1

  公开（公告）日：2009-01-08

  The invention relates to novel compounds of formula (I): H 2 N—CH(R 1 )—CH 2 —S—S—CH 2 —CH(R 2 )—CONH—R 5 , wherein R 1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R 2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5 or 6 atom heterocycle; R 5 is a CH(R 3 )—COOR 4 radical, wherein R 3 is hydrogen, an OH or OR group, a saturated hydrocarbon group, a phenyl or benzyl radical and OR 4 is hydrophile ester, or 5 or 6 membered heterocycle comprising several heteroatoms selected from a group consisting of nitrogen, sulphur and oxygen, with at least two nitrogene atoms, wherein said heterocycle is substitutable by an alkyl C 1 -C 6 , phenyl or benzyl radical. The use of the inventive compounds in the form of drugs, a pharmaceutical composition comprising said compounds, a pharmaceutically acceptable excipient, the use in conjunction of at least one type of cannabinoid derivative for potentiating the analgesic and antidepressant effect of the novel compounds of formula (I) and/or morphine or the derivatives thereof are also disclosed.

  该发明涉及式(I)的新化合物：H2N—CH(R1)—CH2—S—S— —CH(R2)—CONH—R5，其中R1是一个碳氢链、苯基或苯甲基基团，甲基基团被一个5或6原子杂环取代；R2是一个苯基或苯甲基基团，一个5或6原子芳香杂环，甲基基团被一个5或6原子杂环取代；R5是一个CH(R3)—COOR4基团，其中R3是氢、一个OH或OR基团、一个饱和碳氢基团、一个苯基或苯甲基基团，OR4是亲水酯基，或者由氮、硫和氧组成的几个杂原子选自的5或6元杂环，至少有两个氮原子，其中所述杂环可被一个烷基C1-C6、苯基或苯甲基基团取代。该发明化合物的用途包括作为药物、包含所述化合物的药物组合物、药用可接受的赋形剂，以及与至少一种大麻素衍生物联合使用以增强式(I)式新化合物的镇痛和抗抑郁效果和/或吗啡或其衍生物的效果。
• COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF
  申请人：Jenkins Thomas E.

  公开号：US20110262359A1

  公开（公告）日：2011-10-27

  The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.

  本公开提供了药物组合物及其使用方法，其中药物组合物包括一种前药，该前药提供酶控释放药物的能力，以及一种酶抑制剂，与介导前药中药物酶控释放的酶相互作用，以减弱前药的酶解作用。该公开提供了包括酶抑制剂和含有酶可切割基团的前药的药物组合物，当切割时，促进药物释放。
• Molecular Transporters Based On Alditol Or Inositol And Processes For The Preparation Thereof
  申请人：CHUNG Sung-Kee

  公开号：US20080039421A1

  公开（公告）日：2008-02-14

  The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, it can be effectively used in delivering various biologically active molecules, such as doxorubicin and paclitaxel to target cells.

  这种创新的分子转运化合物显示出在生物膜（如细胞膜、细胞核膜和血脑屏障）中具有显著的高透过性，因此可以有效地用于将各种生物活性分子（如阿霉素和紫杉醇）传递到目标细胞中。
• [EN] METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN<br/>[FR] MÉTHODES DE DÉTECTION DE TROUBLES NEUROLOGIQUES PAR LIAISON À UNE PROTÉINE TAU PHOSPHORYLÉE
  申请人：SARRAF STELLA

  公开号：WO2021055639A1

  公开（公告）日：2021-03-25

  Provided herein are methods and compositions for determining whether a patient suffers from a neurological disease or disorder is provided, comprising detecting the presence of a phosphorylated tau protein in a tissue of the patient, wherein the detecting comprises contacting the phosphorylated tau protein with a compound described herein.

  本文提供了一种确定患者是否患有神经系统疾病或紊乱的方法和组合物，包括检测患者组织中磷酸化tau蛋白的存在，其中检测包括将磷酸化tau蛋白与本文描述的化合物接触。
• METHOD FOR PREPARING 1,6:2,3-DIANHYDRO-BETA-D-MANNOPYRANOSE
  申请人：Grossi Pierre Jean

  公开号：US20110213141A1

  公开（公告）日：2011-09-01

  The invention relates to a method for preparing 1,6:2,3-dianhydro-â-D-mannopyranose and is characterized in that it includes a step of cyclizing the compound C, where R is an alykyl group and R′ is an activating agent, in an alcohol/alcoholate mixture under anhydrous conditions.

  本发明涉及一种制备1,6:2,3-二去氢-α-D-甘露糖的方法，其特征在于包括在无水条件下，在醇/醇酸盐混合物中环化化合物C的步骤，其中R为烷基，R'为活化剂。